Septic encephalopathy with confusion and agitation occurs early during sepsis and contributes to the severity of the disease. A decrease in the sphingosine-1-phosphate (S1P) blood levels has been shown in patients and in animal models of sepsis. The lipid mediator S1P is known to be involved in endothelial barrier function in a context-dependent manner. We utilized lipopolysaccharide (LPS)-injected mice as a model for septic encephalopathy and first performed tracer permeability assays to assess the blood-brain barrier (BBB) breakdown in vivo. At time points corresponding to the BBB breakdown post LPS injection, we aimed to characterize the regulation of the sphingolipid signaling pathway at the BBB during sepsis. We measured sphingolipid concentrations in blood, in mouse brain microvessels (MBMVs), and brain tissue. We also analyzed the expression of S1P receptors, transporters, and metabolizing enzymes in MBMVs and brain tissue. Primary mouse brain microvascular endothelial cells (MBMECs) were isolated to evaluate the effects of LPS on transendothelial electrical resistance (TEER) as a measure of permeability in vitro. We observed a relevant decrease in S1P levels after LPS injection in all three compartments (blood, MBMVs, brain tissue) that was accompanied by an increased expression of the S1P receptor type 1 and of sphingosine kinase 1 on one hand and of the S1P degrading enzymes lipid phosphate phosphatase 1 (LPP1) and S1P phosphatase 1 on the other hand, as well as a downregulation of sphingosine kinase 2. Application of LPS to a monolayer of primary MBMECs did not alter TEER, but serum from LPS-treated mice lead to a breakdown of the barrier compared to serum from vehicle-treated mice. We observed profound alterations of the sphingolipid metabolism at the BBB after LPS injection that point toward a therapeutic potential of drugs interfering with this pathway as novel approach for the detrimental overwhelming immune response in sepsis. Keywords: BBB, Inflammation, S1P, Sepsis, Sphingolipids. Sepsis is an exuberant inflammatory reaction to an infectious agent that impairs the body's own tissues and organs (Fleischmann et al. 2016; Singer et al. 2016 Abbreviations used: BBB, blood-brain barrier; Cspg4, chondroitin sulfate proteoglycan 4; EGFR, epidermal growth factor receptor; ET-1, endothelin-1; FTY720, fingolimod; GFAP, glial fibrillary acidic protein; LPP1, lipid phosphate phosphatase 1; LPS, lipopolysaccharide; MBMECs, mouse brain microvascular endothelial cells; MBMVs, mouse brain microvessels; NG2, neuron glial antigen 2; NVU, neurovascular unit; OSCC, oral squamous cell carcinoma; PAF, platelet-activating factor; P-gp, P-glycoprotein; S1PL/Sgpl1, sphingosine-1-phosphate lyase; S1PR, S1P receptor; Sgpp1, sphingosine-1-phosphate phosphatase 1; SMase, sphingomyelinase; SphK, sphingosine kinase; TEER, trans-endothelial electrical resistance TLR4Toll-like receptor 4; TMR, tetramethylrhodamine; TNF-a, tumor necrosis factor-a.
Sepsis is an exuberant inflammatory reaction to an infectious agent that impairs the body's own tissues and organs (Fleischmann et al. 2016; Singer et al. 2016) . Septic encephalopathy, which clinically manifests itself with confusion and agitation and coma at later stages is increasingly recognized as an early symptom of sepsis and is one of the three items of the novel qSOFA screening score for sepsis (Singer et al. 2016) . Lipopolysaccharides (LPS) are membrane components of gram-negative bacteria, frequent causes of sepsis and part of these LPS enter the circulation and act as endotoxins (Frej et al. 2016 ) altering microvascular homeostasis (Goldenberg et al. 2011 ) and blood-brain barrier (BBB) permeability (Danielski et al. 2017) . LPS binds with high affinity to the Toll-like receptor 4 (TLR4) and CD14 which triggers the inflammasome cascade in immune cells such as monocytes, macrophages, and other lymphocytes (Abreu & Arditi 2004 , MacKichan & DeFranco 1999 , Leon et al. 2008 , Guijarro-Munoz et al. 2014 culminating in the massive production of pro-inflammatory cytokines such as tumor necrosis factor-a (TNF-a), IL-1b, and IL-6. In the brain, microglia are resident macrophages, which along with astrocytes are activated by LPS, produce pro-inflammatory cytokines and contribute to inflammation (Dheen et al. 2007) . Under homeostasis, the BBB is a highly selective permeability barrier, separating the microenvironment of the CNS from the peripheral circulation. Microvascular brain endothelial cells, the principal site of the BBB, are tightly sealed and together with astrocytes, pericytes, extracellular matrix, and neuronal processes form the neurovascular unit, which regulates microvascular permeability and cerebral microcirculation (Gurnik et al. 2016) . At the BBB, LPS has been shown to induce inflammatory activation of astrocytes (Sambasivarao and McCluer 1964) and microglia (Nayak et al. 2010) , detachment of pericytes from the basal lamina, neuronal loss (Nishioku et al. 2009) , and to alter the function of tight junctions leading to BBB leakage (Banks et al. 2015) . Sphingolipids are a major class of lipids mainly derived from the membrane lipid sphingomyelin which is hydrolyzed to form ceramides and sphingosine via the action of enzymes sphingomyelinases and ceramidases, respectively. Sphingosine thus formed is phosphorylated to Sphingosine-1-Phosphate (S1P) by two sphingosine kinase isoforms, SphK1 and SphK2 (Brunkhorst et al. 2014) . S1P levels in plasma are in the micro molar range, while much lower levels are present in the interstitium of tissues. This S1P gradient that regulates immune cell distribution (Zhao et al. 2015) and contributes to endothelial function (Rosenberg and Stern 1966) is maintained by conversion of S1P to sphingosine within cells by S1P phosphatases (Spp1 and Spp2) and extracellularly by lipid phosphate phosphatases (LPP1 and LPP3) (Olivera et al. 2013) . In addition, S1P is also irreversibly hydrolyzed within the cells by S1P lyase (S1PL) to produce phosphoethanolamine and palmitaldehyde (Blaho and Hla 2014) . Sphingosine kinases 1 and 2 are intracellular iso-enzymes with distinct localizations and functions (Pyne et al. 2009) (Weigert et al. 2010) . SphK1 has been found to be involved in inflammatory pathways as several cytokines are known to change its localization to plasma membrane and activate the kinase (Wattenberg et al. 2006; Schroder et al. 2011) . In early in vitro studies, it was shown that SphK1 gene inhibition can be beneficial to suppress proinflammatory IL-1b, TNF-a, and other cytokines released by microglia (Nayak et al. 2010) . But recently, through a SphK1 gene deletion approach, the SphK1/S1P axis was found to ameliorate inflammation in lung and brain models of LPS infection by confining inflammation markers (Grin'kina et al. 2012; Ebenezer et al. 2017) .
In a large human cohort of sepsis patients, concentration of S1P in plasma was reported to be decreased and the extent of the decrease correlated with the severity of sepsis. These findings were confirmed in other sepsis models of baboons, rats, and in mice (Winkler et al. 2015; Coldewey et al. 2016; Frej et al. 2016) . In this context it is important to note that the role of S1P via S1P 1 receptor activation is well accepted to be critical in the maintenance of endothelial barrier both in vitro and in vivo (Garcia et al. 2001; Sanna et al. 2006; Wiltshire et al. 2016) . Moreover, vascular leakage associated with S1P decrease in plasma was shown to be reversed in rats treated with fingolimod and S1P intravenous administration was also demonstrated to restore barrier function in rodent and canine models of lung injury (McVerry et al. 2004; Lundblad et al. 2013) .
The aim of this study was to investigate the effects of systemic LPS endotoxemia on the sphingolipid metabolism at the neurovascular unit with a focus on the barrier-active signaling molecule S1P.
Methods

Animals
All animal experiments in this study conformed to the German Protection of Animals Act and the guidelines for care and use of laboratory animals by the local committee (Regierungspraesidium Darmstadt, approval number FU/1014). Male C57BL/6 mice at 7-9 weeks old (RRID: IMSR_JAX:000664) were purchased from Charles River (Sulzfeld, Germany) and were kept on a 12/12 h day/ light cycle with ad libitum food and water.
Lipopolysaccharide (LPS)-induced sepsis in mice
Male C57BL/6 mice aged 7-9 weeks weighing between 18.9 and 21.3 g were given intraperitoneal injections of 4 mg/kg lipopolysaccharide (LPS) from E-coli (Serotype 055:B5; Sigma Aldrich, Taufkirchen, Germany) dissolved in sterile saline (0.9% NaCl) or placebo (saline). Mice were randomly allocated to receive LPS or placebo by means of a computer-generated list (http://rqube.seifseit.de). The solutions were applied by KD, while RV, RIK, and LH performed all further experiments in a blinded fashion until all raw data were ascertained. After 4 h, mice were anesthetized with a mixture of (5 mg/ kg) xylazine (100 mg/kg) ketamine in 0.9% NaCl solution injected i.p. Blood was collected via heart puncture followed by transcardiac perfusion with sterile phosphate-buffered saline (PBS) (Gibco, Rockville, MD, USA). We chose this combination of anesthetics because it allows deep anesthesia and contrary to isoflurane, which has been shown to induce sphingosine kinase expression and ameliorate experimental models of neurological diseases (Altay et al. 2012; Bakar et al. 2012; Yung et al. 2012) , there are no reports of enzyme induction of the sphingolipid pathway by these two drugs. Brain and kidneys were harvested and hemi-brain and kidney were utilized for permeability assay following tracer injection and other hemi-brain was utilized for cryo fixation in Tissue TEK â O.C.T. Compound (Sakura, Staufen, Germany). For lipid and expression analysis of the microvessels and whole brain, whole brain without cerebellum and olfactory lobes was used.
Sample size calculation, a priori power analysis, and study planning The two primary endpoints were changes in sphingolipid mediators.
Besides that, we measured expressional changes of sphingolipid metabolizing enzymes in serum and brain tissue after LPS injection as a model of septic encephalopathy. Concerning the lipid mediator concentrations, we assumed that a change in concentration of 25% would be biologically meaningful. Expecting a within-group standard deviation of 20%, this translated to an expected effect size (Cohen's D) of 1.1. Therefore, we planned 16 mice/group (minimal requirement: 15/group) to detect this effect with a statistical power level of 0.8 and a probability of type A error < 0.05. In a pilot experiment, we had seen maximal BBB disruption at 4 h after LPS injection with gradual recovery thereafter. Therefore, we chose this time point for all further analyses. Additionally, we aimed to explore these changes at the level of isolated microvessels. For this, we planned to randomize 15 animals into each group (LPS and placebo) to obtain five pools of microvessels from three mice/pool.
For the barrier experiments, we planned to isolate primary mouse brain endothelial cells for three independent experiments (6-8 mouse each) testing the barrier effects upon addition of serum of the experimental mice from the LPS or placebo group. The timeline of the study design is detailed in Fig. 1 . The study was not pre-registered.
Permeability assay
After 3.5 h of LPS injection, mice were injected i.p. with (100 lL of 10 mM) 20 kD Tetramethylrhodamine-conjugated dextran (TMR; Sigma Aldrich) and allowed to circulate for 20 min. Then, mice were terminally anesthetized with a mixture of (5 mg/kg) xylazine, (100 mg/ kg) ketamine in 0.9% NaCl solution. For serum samples, arterial blood was collected in a Z-Gel tube (Sarstedt, N€ umbrecht, Germany) by heart puncture and then centrifuged for 10 min at 10 000 g. The mice were perfused with 0.1 M PBS, brain and kidneys were harvested. In order to determine BBB permeability upon LPS treatment, the hemi-brain (free of cerebellum and olfactory lobes) and a single kidney were harvested in 200 or 300 lL PBS respectively, homogenized and centrifuged at 10 000 g for 15 min at 4°C. The supernatant along with serum (diluted 1 : 5 with PBS) was then measured in a fluorescence 384-well plate reader (Tecan Mannedorf, Switzerland) at excitation / emission wavelength 555/585 nm for TMR-20 kD dextran in order to obtain the relative fluorescence units (RFU). The permeability index was calculated as follows:
Tissue RFU=tissue weightðgÞ=ðserum RFU=serum volumeðmLÞ Isolation of mouse brain microvessels Isolation of mouse brain microvessels (MBMVs) was performed as previously described (Gurnik et al. 2016) . Briefly, brains were separated and dissected free of cerebellum and olfactory lobes and rolled on a Whatman filter membrane (Schleicher & Schuell/Sigma Fig. 1 Timeline of the study. Aldrich) to remove meninges, subsequently pooled and homogenized in MVB buffer using a dounce homogenizer (Wheaton, VWR, Darmstadt, Germany, 0.025 mm clearance). The samples were centrifuged at 1000 g for 10 min at 4°C. The resultant pellet was resuspended in 25% bovine serum albumin (BSA) in PBS and centrifuged at 2000 g for 30 min and the upper myelin fat layer was aspirated carefully. The microvessels pellet comprising red blood cells and microvessels was gently resuspended in MVB buffer and strained through a 40 lm nylon mesh (BD) to remove residual myelin debris. The microvessels samples thus obtained were lysed in RLTplus buffer (Qiagen, Hilden, Germany) and stored at À80°C for further extraction of RNA followed by cDNA synthesis for mRNA expression studies.
Isolation of mouse brain microvascular endothelial cells (MBMECs)
A modified protocol was used to isolate endothelial cells for in vitro cell culture experiments (Gurnik et al. 2016) . Concisely, isolated brains free from meninges, cerebellum, and olfactory lobes were pooled and homogenized in a dounce homogenizer (Wheaton, 0.025 mm clearance). The homogenate was digested with 0.75% collagenase II (Worthington, Troisdorf, Germany) in buffer A (153 mM NaCl, 5.6 mM KCl, 1.7 mM CaCl 2 , 1.2 mM MgCl 2, 15 mM HEPES, 10 g/L BSA, pH 7.4) in a (1 : 1 : 1 volume ratio) for 1 h at 37°C on a rocker. Samples were resuspended in 25% BSA and centrifuged at 2000 g for 30 min at 4°C and myelin was discarded. The pellet was further digested with Collagenase/Dispase (Roche, Taufkirchen, Germany) and DNase I (Worthington) in buffer A for 15 min at 37°C. Following centrifugation, microvascular endothelial cells were resuspended in MCDB-131 complete medium (Czupalla et al. 2014 ) and seeded on 6-well plates precoated with type 1 collagen (150 lg/cm 2 , Corning). After 4 h, the medium was replaced with puromycin (5 lg/mL)-containing medium to obtain pure culture of ECs as they express Pglycoprotein (P-gp) that effluxes puromycin, a P-gp substrate. Contaminating cells lacking P-gp (pericytes, astrocytes) fail to survive the treatment. The medium was reverted to puromycin-free medium after 3 days.
Transendothelial electrical resistance (TEER)/capacitance (Ccl) measurements MBMECs (100 000 cells/cm 2 ) were seeded onto 1 lm-pore 24-well PET transwell inserts (Greiner Bio-One, Frickenhausen, Germany) pre-coated with fibronectin (5 lg/cm 2 ; Sigma-Aldrich). The inserts were transferred to a cellZscope â device (NanoAnalytics, Muenster, Germany) placed in a humidified incubator (37°C, 5% CO 2 ) and TEER and Ccl values were obtained from continuous impedance measurements as described previously (Czupalla et al. 2014) .
Treatment with LPS (10 lg/mL) or the serum of LPS-or vehicletreated mice (5% v/v in stimulation medium) was started upon reaching a plateau in TEER/Ccl levels and continued up to 48 h.
Immunofluorescence staining of the cryosections Isolated brains were frozen in the native state in Tissue TEK â O.C.T. compound (Sakura) on dry ice and stored at À80°C. For all stainings, 10 lm coronal brain sections were utilized. Cryosections were thawed and allowed to dry at 24°C for 10 min followed by washing three times for 5 min each with PBS. The sections were permeabilized with 0.1% Triton in PBS for 5 min, incubated with blocking solution (Roti Immuno block blocking solution; Carl Roth, Karlsruhe, Germany) for 1 h at 24°C and then with primary antibody overnight (1 : 200 dilution, unless otherwise mentioned) at 4°C. On the following day, the slides were washed, incubated with an Alexa Fluor fluorescence-conjugated secondary antibody (1 : 400, unless otherwise mentioned) for 1 h at 24°C. The tissue sections were counter-stained with DAPI (4 0 ,6-diamidino-2-phenylindole) and were mounted with fluorescent mounting medium (Dako, Agilent, Santa Clara CA, USA). The sections were imaged on a Nikon Eclipse 80i microscope (Nikon, D€ usseldorf, Germany) with 409 objective n = 5 per group were analyzed) ( Table 1) .
Total RNA extraction from whole brain and MBMVs and mRNA quantification RNA isolation from whole brain homogenate and MBMVs was performed using Master pure complete DNA and RNA isolation kit (Epicenter, Oldendorf, Germany) and RNeasy Plus Micro Kit (Qiagen, Duesseldorf, Germany) according to the manufacturer's instructions, respectively. cDNA was synthesized from 1 lg of total RNA using RevertAid Reverse Transcriptase kit (Thermo Scientific, Darmstadt, Germany). TaqMan â Gene Expression Assay was used for the qRT PCR analysis. The reaction of qRTPCR was performed in appliedbiosystems 96-well PCR plates (Thermo Scientific), sealed with a Clear Seal Diamond Heat Sealing Film (Thermo Scientific) and run in a AB7500 fast system (Applied Biosystems via Thermo Scientific, Foster City, CA, USA). The probes for TNF-a (Mm00443258), IL-1b (Mm00434228), glial fibrillary acidic protein (Mm01253033), chondroitin sulfate proteoglycan 4 (neuron glial antigen 2) (Mm00507257), Sgpl1 (Mm00486079), sphingosine-1-phosphate phosphatase 1 (Sgpp1) (Mm00473016), Sgpp2 (Mm03039020), Ppap2a (LPP1) (Mm00477016), Ppap2c (LPP3) (Mm01147288), SphK1 (Mm01252547), SphK2 (Mm01194024), Gapdh (Mm99999915), CD-31 (Mm01242584) from Life Technologies (Grand Island, NY, USA) were used and the changes in the mRNA levels were calculated according to 2 ÀDDCT method. Determination of sphingolipid concentrations by high-performance liquid chromatography tandem mass spectrometry The quantitation of sphingolipids was done in a syngenic fashion for compartmental analysis. Whole brain homogenates from two animals were pooled and amount corresponding to 1 mg brain tissue was stored on dry ice. The remaining homogenate was subjected to isolation of microvessels and whole sample was stored for lipid measurement. Equal amounts of serum from the same two animals were pooled and 10 lL was used for lipid analysis. Serum samples were mixed with 190 lL water before the extraction. The sample was mixed with 200 lL extraction buffer (citric acid 30 mM, disodium hydrogen phosphate 40 mM) and 20 lL of the internal standard solution containing sphingosine-d7, sphinganined7 (200 ng/mL each), C18-sphingosine-1-phosphate-d7, C17:0 Cer, C16:0 Cer-d31, C17:0 LacCer, C18:0 GluCer-d5 (all Avanti Polar Lipids; Alabaster, AL, USA), C18:0 Cer-d3, C18:0 DHC-d3, C16:0 LacCer-d3 (all Matreya, State College, PA, USA), and C24:0 Cerd4 (Chiroblock GmbH, Bitterfeld-Wolfen, Germany) (400 ng/mL methanol each). The mixture was extracted once with 1000 lL methanol/chloroform/hydrochloric acid (15 : 83 : 2, v/v/v). The organic phase was evaporated and reconstituted in 100 lL of tetrahydrofuran/water (9 : 1, v/v) with 0.2 formic acid and 10 mM ammonium formate. C20-sphingosine-1-phosphate was determined semiquantitatively by means of a C20-S1P standard. We did not have an isotopically labeled internal standard of C20-S1P.
An Agilent 1100 series binary pump (Agilent Technologies, Waldbronn, Germany) equipped with a Luna C8 column (150 mm 9 2 mm ID, 3 lm particle size, 100 A pore size; Phenomenex, Aschaffenburg, Germany) was used for chromatographic separation under gradient conditions. The HPLC mobile phases consisted of water with 0.2% formic acid and 2 mM ammonium formate (mobile phase A) and acetonitrile/isopropanol/ acetone (50 : 30 : 20, v/v/v) with 0.2% formic acid (mobile phase B). The total running time was 21 min and the injection volume was 15 lL. Acetonitrile with 0.1% formic acid was infused post-column using an isocratic pump at a flow rate of 0.15 mL/min. The MS/MS analyses were performed using a triple quadrupole mass spectrometer API4000 (Sciex, Darmstadt, Germany) equipped with a Turbo V Ion Source operating in positive electrospray ionization Multiple Reaction Monitoring mode.
Data Acquisition was done using Analyst Software V 1.6 and quantification was performed with MultiQuant Software V 3.0 (both Sciex), employing the internal standard method (isotope dilution mass spectrometry).
Western blotting
The protein volume (40 lg/well) of microvessels were solubilized in urea/sodium dodecyl sulfate (SDS) buffer (2.3 M urea, 1.5% SDS, 50 mM Tris, 25 mM TCEP and 0.01% BPB) for 1 h at 30°C with shaking. The protein samples were then electrophoresed by SDS-polyacrylamide gel electrophoresis (10%) and subsequently electroblotted onto nitrocellulose membranes via wet transfer at 4°C overnight. The efficiency of the protein transfer onto the membranes was verified through Ponceau S staining for 10 min. Later the membranes were thoroughly washed with PBST (0.1% Tween 20 in PBS) and deionized water. The membranes were then blocked with blocking solution (19 Roti â -block; Roth, Karlshruhe, Germany) for 1 h at 24°C, incubated with primary antibodies for 2 h (Table 2) at 24°C, washed three times for 10 min with PBST and finally incubated with fluorescent-conjugated secondary antibodies (Table 3) for 1 h at 24°C. After secondary antibody incubation, the membranes were washed with PBST and imaged in the Odyssey (LI-COR Bad Homburg, Germany) imaging device. All the quantifications were performed using Image Studio 2.1 software (LI-COR) as described previously (Gurnik et al. 2016) .
Statistical analysis
All statistical analyses were performed using GraphPad Prism 7.0 software (La Jolla, CA, USA). Statistical significance of the differences observed between the two experimental groups was tested with unpaired student's t-test, p value below 0.05 was considered to be statistically significant. The number of animals, experimental repeats and the specific statistical test employed is indicated in the corresponding figure legends.
Results
LPS treatment induces BBB permeability, up-regulates proinflammatory cytokines, and activates immunoreactive cell types in the brain The impact of LPS on BBB permeability in vivo was studied by injecting the fluorescent tracer TMR 20kD dextran to mice after 4 h of endotoxin treatment. A single dose of LPS (4 mg/kg) was sufficient to induce a significant leakage of the tracer (Fig. 2a) into the brain tissue compared to that of control mice treated with saline. Kidneys served as a control for the tracer permeability with no changes between the LPStreated and the control group. In order to confirm that inflammatory response was established in the brain, we analyzed the mRNA expression of different cytokines and inflammatory markers in whole brain homogenates using qRT-PCR. The expression of the pro-inflammatory cytokines, TNF-a and IL-1b, were highly up-regulated in the whole brain following LPS treatment (Fig. 2b) . These proinflammatory cytokines were reported to be produced by microglia upon activation during sepsis (Nayak et al. 2010) implying their role in LPS-mediated BBB disruption. Similarly, the mRNA and protein expression of activation markers of immunoreactive cell types of the BBB such as astrocytes glial fibrillary acidic protein and pericytes (neuron/glial antigen neuron glial antigen 2) were also found to be significantly increased after LPS treatment in comparison to the control animals ( Fig. 2b and c) . acidic protein) and pericyte (NG2/CSPG4 -neuron-glial antigen 2/ chondroitin sulfate proteoglycan 4) activation from whole brain homogenate normalized to GAPDH. n = 11-16 individual mice per group. Statistical significance was assessed by unpaired two-tailed student's ttest. *p < 0.05; **p < 0.01, ***p < 0.001. (c) IF on coronal brain sections in the cortex region of LPS and placebo. Representative images from n = 5 mice per group and three images from each mice.
Alterations of sphingolipid levels in serum, whole brain homogenates, and microvessels in LPS-induced sepsis in mice We quantified the levels of various sphingolipids in serum, whole brain homogenate and mouse brain microvessels 4 h after LPS or saline injection. S1P is considered to be important for promoting barrier maintenance and we found that the concentrations of S1P (C18 and C20) were significantly reduced in serum of LPS-treated mice in comparison to control mice. A significant reduction in S1P (C18 and C20) levels was also observed in whole brain homogenates and a similar tendency was observed in homogenates of isolated mouse brain microvessels (Fig. 3a) . By contrast, sphingosine levels increased significantly after LPS injection in serum and MBMVs, while sphingosine in the brain was above the measurement range in saline-and Figure S1) . Along with S1P, ceramides with different chain lengths (C16, C18, C20, C24, C24:1) were also measured in serum and different brain compartments. In serum, different chain length ceramides except C18 were significantly increased in LPS-treated mice (Fig. 3b) , while interestingly, there were no changes in ceramide levels in whole brain homogenates or in isolated brain microvessels (Supplementary Figures S2a and b) .
LPS-injected mice (Supplementary
Systemic LPS endotoxemia modulates the expression of sphingolipid metabolizing enzymes in the brain and in brain microvessels To understand the mechanism of the observed changes in sphingolipid levels in LPS endotoxemia, we analyzed the mRNA expression of S1P generating and metabolizing enzymes in brain and brain microvessels by qRT-PCR. Both (a) (b) Fig. 3 Lipopolysaccharide (LPS) treatment reduces S1P levels in serum and brain and enhances ceramide generation in serum. (a) C18-S1P and C20-S1P levels in serum (n = 7-8 individual mice per group), whole brain homogenate (n = 12 individual mice per group) and MBMVs (n = 4-5 independent isolations of three mice/ isolation) as determined by LC-MS/MS. (b) Levels of different chain length ceramide species as indicated in serum (n = 6-14 individual mice) as determined by LC-MS/ MS. Statistical significance was assessed by unpaired two-tailed student's t-test. *p < 0.05; **p < 0.01, ***p < 0.001. in whole brain homogenates and brain microvessels, LPS treatment induced the mRNA up-regulation of SphK 1 but not its isoenzyme SphK2 (Fig. 4a and b) . WB confirmed an increase in SphK1 expression and showed a down-regulation of SphK2 that must occur post-translationally since SphK2 mRNA levels did not change (Fig. 5) . Among the S1P degrading enzymes that operate extracellularly, mRNA expression of LPP1 was doubled after LPS treatment in both of the microvessel compartment and the whole brain, whereas LPP3 expression was not altered significantly ( Fig. 4a and b) . The S1P-degrading phosphatases acting intracellularly show a similar pattern of differential upregulation with increased mRNA expression levels of Sgpp1 after LPS treatment, while Sgpp2 expression remains constant ( Fig. 4a and b) . Protein levels of both S1P phosphatases were regulated in the same way. S1P in cells is irreversibly degraded by S1P lyase. The mRNA levels of the S1P lyase were not changed by LPS treatment neither in whole brain homogenates nor in brain microvessels.
Systemic LPS endotoxemia leads to a selective up-regulation of S1P receptor type 1 in MBMVs, while BBB tight junction proteins are down-regulated One way how the microvasculature could compensate the drop in plasma S1P in sepsis is by up-regulation of S1P receptors. We analyzed the mRNA expression levels of the five S1PRs (S1PR1-5) in MBMVs 4 h after LPS injection and found a selective up-regulation of S1PR1 in comparison to the expression level in vehicle-treated mice (Fig. 5a ), while S1PR2, S1PR3, and S1PR4 expression was not altered and S1PR5 is not expressed in MBMVs (data not shown). At the same time, we saw reduced mRNA and protein levels of claudin-5, a crucial regulator of BBB function (Fig. 6b and  c) .
LPS does not affect the permeability of the MBMEC monolayer, but serum from LPS-treated animals increases permeability To assess whether LPS disrupts barrier function in an in vitro model of the BBB, primary MBMECs were isolated and subjected to long-term measurements of transendothelial electrical resistance (TEER) as an indicator of endothelial barrier function (Fig. 7) . Addition of LPS to the medium (10 lg/mL) did not significantly reduce TEER in comparison with vehicle ( Fig. 5a and b) . We did not observe a significant difference in TEER between LPS-and vehicle (PBS)-treated primary brain endothelial cells over the whole course of the experiment, which suggests that LPS alone has no direct effect on brain endothelial permeability. To investigate if LPS affects of vascular permeability in vivo were indirect resulting from serum factors (e.g., lipid mediators or cytokines), MBMECs were treated with serum isolated from LPS or PBS injected mice. Addition of serum from LPS injected animals lead to a sustained decrease in TEER up to Fig. 4 Characterization of the sphingolipidgenerating and metabolizing enzymes after lipopolysaccharide (LPS) treatment in whole brain homogenate and brain microvessels. (a) mRNA expression of sphingosine kinases 1 and 2 (SphK1 and SphK2), S1P-Lyase (Sgpl1), S1P phosphatases 1 and 2 (Sgpp1 and Sgpp2), and lipid phosphate phosphatases 1 and 3 (LPP1 and LPP3) in whole brain homogenate normalized to GAPDH and in (b) MBMVs normalized to CD31/PECAM-1, n = 4-5 independent isolations of three mice/isolation. Statistical significance was assessed by unpaired twotailed student's t-test. *p < 0.05; **p < 0.01. 48 h post treatment, indicating loss of barrier properties. These findings suggests that the LPS-mediated BBB damage is because of an indirect effect of cytokines such as TNF-a and IL-1b that are known to open the barrier and not a direct LPS-mediated effect. The observed vascular permeability could also be potentially because of loss of lipids in the serum from LPS-treated mice as shown in Fig. 2 for S1P that has been shown previously to be barrier protective (Garcia et al. 2001 ).
Discussion
Sepsis is one of the major health concerns worldwide and causes several pathophysiological changes in the body, including septic encephalopathy. Recently, Sphingolipids have emerged as important signaling molecules in health and diseases. Especially S1P is widely recognized as a modulator of endothelial barrier function. In this study, we analyzed the changes in sphingolipids and their generating and metabolizing enzymes in serum, whole brain homogenate, and brain microvessels following LPS-induced sepsis in mice. To validate our model, we confirmed BBB disruption after LPS injection by 20 kD dextran and, using different cell type markers of the brain, we were able to show their activation following experimental endotoxemia. The key findings of our study were that (i) S1P levels remarkably decreased post LPS injection in serum, whole brain homogenate, as well as in brain microvessels. (ii) Concomitantly, we found on one hand, an increased S1PR1 expression in isolated microvessels, an up-regulation of sphingosine kinase 1 both in brain microvessels and in whole brain homogenates but on the other hand an up-regulation of the S1P degrading enzymes LPP1 and Sgpp1 in brain microvessels and brain homogenates. (iii) We report that specific species of ceramides are significantly increased in serum after LPS treatment. In addition, through in vitro TEER experiments, we could show that (iv) LPS at different concentrations did not directly lead to increased permeability, but the serum from LPS-treated mice rapidly compromised the barrier function of a primary brain endothelial cell monolayer.
The fact that LPS promotes vascular leakage in peripheral endothelial cells is well embraced, but it is still unclear if LPS penetrates BBB (Banks and Robinson 2010; Yung et al. 2012) or indirectly by activating other cell types and their products leads to BBB disruption. While sphingolipids have been shown to be involved in inflammatory processes, the effect of LPS-induced inflammation on the sphingolipid metabolism at the BBB has not been addressed before.
Ceramides are prominent sphingolipids with both structural and regulatory functions. They constitute lipid rafts in the plasma membrane; engage in apoptosis, autophagy, cell cycle arrest, and inflammation (Gomez-Munoz et al. 2016) . We show here that LPS-induced inflammation leads to increased levels of ceramides with different chain lengths in serum, while ceramide levels were unaltered in brain and microvessels after LPS treatment. In one previous study, LPS injection to mice fostered ceramide generation in the tissue of several organs (intestine, lung, fat, and thymus) as early as 1 h after injection which was followed by apoptosis in the endothelial cells of these organs within 6 h (HaimovitzFriedman et al. 1997) . Since we did not analyze ceramides in other organs than the brain, we are not able to make any assumptions on whether the brain and especially the brain microvessels have a reduced capacity of ceramide generation in the context of LPS-induced inflammation. Isolated brain Fig. 5 Expression of the sphingosine kinases and S1P phosphatases after LPS treatment in brain microvessels. Western blot of VE-cadherin (CDH5), b-actin (ACTB), SphK1, SphK2, sphingosine-1-phosphate phosphatase 1 (Sgpp1) and Sgpp2. Mean band densities were normalized to b-actin and mean band densities were compared and the statistical significance of the observed differences was analyzed by two-tailed unpaired t-test (n = 4-5 independent isolations of three mice/isolation). *p < 0.05; ***p < 0.001. microvessels, however, were shown to generate ceramides in reaction to endothelin-1 which is involved in regulating BBB permeability (Collado et al. 2003) . Ceramides are wellacknowledged to be proinflammatory as they are triggered by several cytokines, interleukins, or platelet-activating factor during inflammation. Also, ceramides are involved in generation of prostaglandins via activating cytosolic phospholipase A2 and subsequent arachidonic acid (Goggel et al. 2004; Jenkins et al. 2010) . All these potent activators of sphingomyelinase enzymes generate ceramides and enhance inflammation (Nixon 2009 ). In severe sepsis, eryptosis is triggered mainly by stimulating ceramide production (Lang et al. 2004) .
Sphingosine under physiological conditions serves as a precursor for both ceramides as well as for or S1P synthesis. This rheostat is believed to be vital in maintaining cell and tissue homeostasis . Sphingosine is also known to induce cell death, eryptosis (Qadri et al. 2011) , and has also been implied to enhance permeability of membranes in vitro (Contreras et al. 2006) . In our experiments, we found that sphingosine levels were significantly increased in plasma and MBMVs after LPS treatment in comparison with the placebo group. In brain homogenates, sphingosine levels in both groups exceeded the detection threshold. S1P levels in serum and plasma were reported to be significantly reduced in several diseases like sepsis, septic shock, and dengue fever where vascular leakage is increased in humans and animal models (Jungalwala et al. 1979; Winkler et al. 2015; Coldewey et al. 2016; Frej et al. 2016) . We have demonstrated here that S1P levels in mice decline not only in serum but also in brain and brain microvessels after sepsis. This affects both C18 and C20 S1P. A recent report on the role of serine palmitoyl transferases on neurodegeneration (Zhao et al. 2015) ), which by their affinity to C18 or C20 fatty acyl-CoA substrates determine the abundance of the respective long chain base for sphingolipids, prompted us to investigate C18 and C20 differentially. While this group had shown slightly higher C20 than C18 S1P levels in brain tissue of WT mice, we found C18 to be about 109 more abundant than C20-S1P. Interestingly, we could also detect the long-chain species C20-S1P also in our non-neuronal samples (plasma and MBMVs) in the same C18 : C20 ratio of around 10 : 1. Concerning the abundance of C20-and C18-sphingolipids in different compartments, we found conflicting results, with some groups stating that this C20/C18 shift in the brain tissue mainly concerns gangliosides (Sambasivarao and McCluer 1964; Sonnino et al. 2007; Sonnino & Chigorno, BBA 2000) and increases with age in neurological diseases, whereas others found it in non-complex sphingolipids as well but with a 50 : 50 ratio (Rosenberg and Stern 1966; Schwarz et al. 1967 ) for both chain lengths or even a much lower abundance of C20-bases (Schwarz et al. 1967) . Concerning non-neuronal tissues, very scarce information on the abundance of C20-sphingolipids is available. We found one report on C20 sphingolipids being absent in erythrocytes (Jungalwala et al. 1979) , but erythrocytes have a very distinct enzymatic machinery from many other cells, which might explain this difference.
As possible regulators of S1P levels after LPS injection, we detected increased expression levels of Sgpp1 and LPP1 in brain and microvessels of animals treated with LPS. Based on the increased levels of sphingosine and the expression of S1P phosphatases, it is conceivable that S1P is reversibly dephosphorylated not only in whole brain but also in brain microvessels. Surprisingly, the levels of Sgpp2, LPP3, and Sgpl1 did not differ between the treatment and the control group. Interestingly, we found an up-regulation of S1PR1 on the mRNA level, which may be compensatory to increase S1P signaling in spite of the reduced S1P levels. We also detected an up-regulation in the SphK1 levels pointing toward a compensatory response to increase the S1P levels that are down in the LPS-treated mice, while the expression of SphK2, the predominant SphK in the brain, was posttranslationally down-regulated, possibly contributing to reduced S1P levels after LPS injection. Taken together, these data suggest compensation at both the receptor and the ligand level in response to LPS, and this is potentially at the brain endothelium as S1PR1 and the SphK1 are highly expressed at this site. Recently (Vishwakarma et al. 2017) also showed that in patients with oral squamous cell carcinoma, the S1P phosphatases and sphingosine kinases were differentially regulated in tumors and tumor metastasis. There are conflicting reports on the role of SphK1 in inflammation. While SphK1 deficiency was reported to exacerbate LPS-induced inflammation in vivo (Grin'kina et al. 2012) , it was also shown that SphK1 regulates the expression of proinflammatory cytokines in activated microglia in vitro (Nayak et al. 2010) . Recently, a crosstalk between SphK1 and biglycan was reported to regulate the synthesis of macrophage chemoattractants (Hsieh et al. 2017) .
Contrary to previous findings that BBB disruption occurs only after 24 h following LPS injection (Banks et al. 2015) , we found significantly increased permeability of the 20kD dextran tracer already after 4 h of LPS treatment in vivo (Fig. 1) indicating a considerable disruption of BBB. Although it is still unclear if LPS penetrates BBB, Wang et al. (2016) have shown in vivo, that E-coli causing meningitis crossed the BBB exploiting SphK2-S1P-S1P2-EGFR-c-Src signaling cascade. Furthermore, we found that permeability of the primary brain endothelial cells was not affected by different doses of LPS, but the serum from the same LPS treatment animals rapidly decreased the electrical resistance of the monolayer. We also observed that astrocytes, glial cells and pericytes markers were up-regulated in sepsis, which is a sign of their activation. While glial cells are the resident immune cells of brain, astrocytes and pericytes are the components of neurovascular unit and their role is well documented during inflammation. Taken together, our data support that LPS does not act directly on endothelial cells and it is worthwhile to characterize the LPS-induced serum factors responsible for endothelial barrier disruption in vitro as well as their putative source. Although it is clear that different brain cell types are activated during inflammation, further research is warranted to pinpoint how these cell types or the factors released orchestrate neuroinflammation.
In conclusion, sphingolipids and their receptors are emerging as possible therapeutic targets to limit the consequences of the excessive immune activation in sepsis. It is therefore crucial to gain further insights into the sphingolipid metabolism in inflammatory BBB disruption and the mechanisms involved. Targeting the sphingolipid pathway could offer potential diagnostic and therapeutic options for patients suffering from sepsis.
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